Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.For patients with acute coronary syndromes managed with PCI
Subscribe to our email newsletter
Daiichi Sankyo and Eli Lilly co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and Ube Industries. Effient helps keep blood platelets from clumping together and developing a blockage in an artery.
Effient is approved by the FDA for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes (ACS) who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI).
Effient received the class I recommendation from the Guidelines Committee in both sets of the guideline updates. Consistent with the Effient label, both guidelines provide recommendations to avoid the use of Effient in patients with a prior history of TIA or stroke.
Effient (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates, one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack.
LeRoy LeNarz, senior medical director of cardiovascular care at Lilly USA, said: “It is important that the cardiology community has updated clinical guidelines that include the latest treatment options like Effient for treating ACS patients managed with angioplasty and stenting.
“By recommending Effient, these guidelines recognize an important new treatment for ACS-PCI patients, particularly for those with severe heart attacks who are at increased risk of suffering future cardiovascular events.”
Rogelio Braceras, senior medical director of Daiichi Sankyo, said: “The Guidelines Committee classified prasugrel, marketed in the US as Effient, with a Class I rating. Based on the latest clinical studies and scientific evidence, these guidelines provide clear recommendations for how Effient should be incorporated into medical practice to help reduce risk of cardiovascular events such as heart attacks and blood clots forming around stents.”